Safety and Synovial Inflammatory Response After Intra-articular Injection of Botulinum Toxin Type A in Healthy Horses.
Authors: Beck Antônio Alcemar, Paz Letícia Bisso, Frank Maria Inês, Engelmann Ana Martiele, Krause Alexandre, Côrte Flávio Desessards De La
Journal: Journal of equine veterinary science
Summary
Botulinum toxin type A (BoNT-A) represents an emerging intervention for equine joint pain management, though its safety profile within the synovial environment requires rigorous evaluation before widespread clinical adoption. Researchers administered a single 50 U intra-articular injection of BoNT-A to one radiocarpal joint in eight horses whilst the contralateral joint received saline as control, then monitored systemic parameters (heart rate, temperature, respiratory rate, appetite, attitude) and local joint responses (pain on flexion and palpation, carpal circumference, lameness) twice daily for seven days, alongside synovial fluid analysis at baseline, 24 hours post-injection and 168 hours post-injection. No systemic adverse effects were documented, joint pain and swelling did not develop in treated limbs, and notably lameness was observed only in the saline-treated control limbs, suggesting BoNT-A may offer analgesic benefit; synovial fluid parameters showed expected mild inflammatory elevation at 24 hours that resolved by day seven, indicating a self-limiting response. Whilst the study provides reassuring preliminary safety data, the modest sample size and single-dose protocol mean findings should be interpreted cautiously and further investigation is needed to establish optimal dosing, appropriate indications, duration of effect, and long-term cartilage safety before practitioners consider this approach in clinical cases.
Read the full abstract on PubMed
Practical Takeaways
- •BoNT-A shows promise as a potential therapeutic option for managing chronic joint pain in horses, with no apparent systemic or local toxicity at the tested dose
- •Mild synovial inflammation occurs within 24 hours of injection but resolves within one week, which may be part of the mechanism of action rather than a contraindication
- •Current evidence is limited to a small pilot study; practitioners should await results of larger randomized controlled trials before implementing this treatment clinically
Key Findings
- •Single intra-articular injection of 50 U BoNT-A produced no clinically significant adverse effects on heart rate, respiratory rate, rectal temperature, or other systemic clinical parameters in 8 horses over 7 days
- •No joint pain, swelling, or lameness was induced by BoNT-A treatment in the injected joint, whereas saline-injected limbs showed lameness
- •Synovial fluid cellular parameters increased significantly at 24 hours post-injection but returned toward baseline by 168 hours, indicating a mild transient inflammatory response
- •50 U BoNT-A injection appears safe for intra-articular use in horses but requires further investigation in larger studies